27662437|t|Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome
27662437|a|Adults with Prader-Willi syndrome (PWS) have an increased proportion of sc fat mass compared with body mass index (BMI)-matched controls, but whether the genotype influences body composition and metabolic profile remains controversial. To assess body composition and metabolic features in adults with PWS, according to genetic subtype. In addition, the effect of previous GH treatment was assessed. Main Outcomes and Measures: Body composition (Dual Energy X-ray Absorptiometry) and metabolic parameters were compared in PWS adults (mean age, 25.5 ± 8.9 y) with deletion (n = 47) or uniparental disomy (UPD) (n = 26), taking into account GH treatment in childhood and/or adolescence. In subgroups, adipocyte size, fasting total ghrelin levels, and resting energy expenditure were measured, and hyperphagia was assessed by the Dykens Hyperphagia Questionnaire. In the whole sample, the deletion group had a higher BMI compared with UPD (40.9 ± 11.5 vs 34.6 ± 9.6 kg/m(2), P = .02), but there was no difference between groups in percent body fat, metabolic profile, adipocyte size, resting energy expenditure, hyperphagia score, or ghrelin levels. In subjects previously treated with GH, BMI was not different between UPD and deletion groups (33.0 ± 9.7 vs 33.5 ± 11.1 kg/m(2)). In addition, previous GH treatment was associated with decreased percent body fat and adipocyte volume only in the deletion group. A deletion genotype in adults with PWS is associated with increased BMI. GH treatment in childhood and/or adolescence limits this deleterious phenotypic effect with improved adiposity markers. This study suggests relationships between the molecular phenotype of PWS and adipose tissue development as well as sensitivity to GH.
27662437	0	6	Effect	T080	C1280500
27662437	10	18	Genotype	T032	C0017431
27662437	32	44	GH Treatment	T047	C0744483
27662437	48	57	Adiposity	T032	C1563743
27662437	61	67	Adults	T100	C0001675
27662437	73	94	Prader-Willi Syndrome	T019	C0032897
27662437	95	101	Adults	T100	C0001675
27662437	107	128	Prader-Willi syndrome	T019	C0032897
27662437	130	133	PWS	T019	C0032897
27662437	167	173	sc fat	T024	C0222331
27662437	174	178	mass	T081	C3152252
27662437	193	208	body mass index	T201	C1305855
27662437	210	213	BMI	T201	C1305855
27662437	223	231	controls	T096	C0009932
27662437	249	257	genotype	T032	C0017431
27662437	269	285	body composition	T032	C0005885
27662437	290	307	metabolic profile	T039	C3853758
27662437	341	357	body composition	T032	C0005885
27662437	362	380	metabolic features	T201	C1864620
27662437	384	390	adults	T100	C0001675
27662437	396	399	PWS	T019	C0032897
27662437	414	429	genetic subtype	T032	C0017431
27662437	467	479	GH treatment	T047	C0744483
27662437	484	492	assessed	T052	C1516048
27662437	499	507	Outcomes	T080	C0085415
27662437	512	520	Measures	T081	C0079809
27662437	522	538	Body composition	T032	C0005885
27662437	540	572	Dual Energy X-ray Absorptiometry	T060	C1510486
27662437	578	598	metabolic parameters	T033	C0243095
27662437	616	619	PWS	T019	C0032897
27662437	620	626	adults	T100	C0001675
27662437	657	665	deletion	T045	C0017260
27662437	678	696	uniparental disomy	T049	C0949628
27662437	698	701	UPD	T049	C0949628
27662437	733	745	GH treatment	T047	C0744483
27662437	749	758	childhood	T079	C0231335
27662437	766	777	adolescence	T079	C0001578
27662437	793	807	adipocyte size	T081	C0392762
27662437	809	816	fasting	T033	C0015663
27662437	817	837	total ghrelin levels	T059	C3813179
27662437	843	869	resting energy expenditure	T033	C0429629
27662437	875	883	measured	T080	C0444706
27662437	889	900	hyperphagia	T033	C0020505
27662437	905	913	assessed	T052	C1516048
27662437	921	953	Dykens Hyperphagia Questionnaire	T170	C0034394
27662437	980	994	deletion group	T098	C1257890
27662437	1001	1007	higher	T080	C0205250
27662437	1008	1011	BMI	T201	C1305855
27662437	1026	1029	UPD	T049	C0949628
27662437	1122	1138	percent body fat	T033	C0518026
27662437	1140	1157	metabolic profile	T039	C3853758
27662437	1159	1168	adipocyte	T025	C0206131
27662437	1169	1173	size	T081	C0162658
27662437	1175	1201	resting energy expenditure	T033	C0429629
27662437	1203	1214	hyperphagia	T033	C0020505
27662437	1215	1220	score	T081	C0449820
27662437	1225	1239	ghrelin levels	T059	C3813179
27662437	1244	1252	subjects	T062	C0178693
27662437	1264	1276	treated with	T061	C0332293
27662437	1277	1279	GH	T116,T121,T125	C0037663
27662437	1281	1284	BMI	T201	C1305855
27662437	1311	1314	UPD	T049	C0949628
27662437	1319	1334	deletion groups	T098	C1257890
27662437	1394	1406	GH treatment	T047	C0744483
27662437	1411	1426	associated with	T080	C0332281
27662437	1437	1453	percent body fat	T033	C0518026
27662437	1458	1467	adipocyte	T025	C0206131
27662437	1468	1474	volume	T081	C0596292
27662437	1487	1501	deletion group	T098	C1257890
27662437	1514	1522	genotype	T032	C0017431
27662437	1526	1532	adults	T100	C0001675
27662437	1538	1541	PWS	T019	C0032897
27662437	1545	1560	associated with	T080	C0332281
27662437	1571	1574	BMI	T201	C1305855
27662437	1576	1588	GH treatment	T047	C0744483
27662437	1592	1601	childhood	T079	C0231335
27662437	1609	1620	adolescence	T079	C0001578
27662437	1645	1662	phenotypic effect	T190	C4021819
27662437	1677	1686	adiposity	T032	C1563743
27662437	1687	1694	markers	T045	C0017393
27662437	1701	1706	study	T062	C2603343
27662437	1716	1729	relationships	T080	C0439849
27662437	1752	1761	phenotype	T032	C0031437
27662437	1765	1768	PWS	T019	C0032897
27662437	1773	1787	adipose tissue	T024	C0001527
27662437	1788	1799	development	T169	C1527148
27662437	1826	1828	GH	T116,T121,T125	C0037663